Elixir Medical

EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years

Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX compared to DES Significantly lower rate of Cardiac Death (0.5% versus 3.2%, p=0.033) with DynamX compared to DES 21 May 2025 -- Paris, France -- Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, today announced...
920 N. McCarthy Blvd. Milpitas, CA 95035 U.S.

+1.408.636.2000